Director Declaration

Life Science REIT PLC

11 October 2023

 

11 October 2023

LEI 213800RG7JNX7K8F7525

Life Science REIT plc

("Life Science REIT" or the "Company")

Director Declaration

Claire Boyle, Chair and Non-Executive Director of Life Science REIT, has been appointed to the Board of Nippon Active Value Fund plc, a company listed on the London Stock Exchange, with effect from 10 October 2023. In addition, Claire Boyle has resigned from her appointment as an Independent Non-Executive Director of abrdn Japan Investment Trust plc with effect from 10 October 2023.

This disclosure is made in accordance with Listing Rule 9.6.14.

Enquiries:

Link Company Matters Limited - Company Secretary
[e-mail]
Ironstone Asset Management - Investment Adviser
Simon Farnsworth/ Joanna Waddingham	via Buchanan below
Panmure Gordon - Joint Corporate Broker	[phone]
Alex Collins / Tom Scrivens
Jefferies International Limited - Joint Corporate Broker	[phone]
Tom Yeadon / Andrew Morris / Oliver Nott
G10 Capital Limited - AIFM	[phone]
Verity Morgan-Jones / Paul Cowland
Buchanan - Financial PR	[phone]
Mark Court / Henry Wilson / Verity Parker
[e-mail]

Notes to editors

Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.

Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is benefiting from a buoyant early-stage funding environment, driving demand for laboratory space.    

The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.

The Company's investment policy is focused on capital growth whilst also providing a growing level of income.

Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.

Further information is available at https://lifesciencereit.co.uk. To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.

 

END